Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

After he was diagnosed, Olson dropped out of college, moved back in with his parents, and began Weiner's prescribed regimen: ...

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

Anthony Olson was told he’d die without treatment and to ignore a negative biopsy. He’s one of many patients who may have ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic ...

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide ...

Panelists discuss how the NCCN Guidelines define lower-risk myelodysplastic syndrome (LR-MDS) based on clinical hallmarks such as anemia and cytopenias, with treatment decisions guided by prognostic ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.